Press release
ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer
ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need.
Image: https://www.globalnewslines.com/uploads/2025/07/5b4b64d3d25a93a3b2f4f1dadf688558.jpg
These positive developments highlight the significant market potential of ISOT-101 in the NERD PPI-PR segment, an estimated 15-30 million patients in the U.S alone who are inadequately addressed by current gold standard therapies and a multi-billion-dollar annual company market opportunity.
In light of this clinical and commercial potential, long-time ISOThrive board member and pharmaceutical industry veteran Mike Walther will expand his role as Chief Strategy Officer. Mr. Walther's 30+ year gastroenterology experience, including the launch of and key leadership roles on blockbuster heartburn medications, Prevacid Registered and Dexilant Registered , will be leveraged to accelerate the company's next stage opportunities, including strategic partnerships and/or M&A.
"This encouraging interim data supports our novel approach and strengthens our development program," said Jack Oswald, CEO. "Our treatment shows the potential to become a leading solution for millions of NERD patients who remain symptomatic despite current treatment options. We believe this progress positions us for a high-value strategic transaction. Bringing a seasoned executive like Mike Walther on board is a critical step in capitalizing on this momentum."
Mike Walther, Chief Strategy Officer, added, "The interim data for ISOT-101 is exceptionally encouraging, suggesting a meaningful impact in a patient population that remains symptomatic with current options. Having been involved with two of the most successful PPIs, I am thrilled to now work even more closely with the executive team at this pivotal moment to help realize the immense potential of this product and accelerate our path forward for a non-acid suppressing, first-of-it's kind microbiome-targeting therapy ."
Study completion scheduled for Q4 2025.
ISOThrive Inc. is developing novel, microbiome-targeted therapeutics for gastrointestinal diseases. Its lead product, ISOT-101, with over 30 global patents, is a first-in-class treatment being evaluated for Non-Erosive Reflux Disease (NERD). ISOThrive.com
Acid Reducing Medications: Omeprazole (Prilosec Registered : AstraZeneca Procter&Gamble, Zegerid Registered : Riley), Esomeprazole (Nexium Registered : AstraZeneca), Lansoprazole (Prevacid Registered : Takeda), Dexlansoprazole (Dexilant Registered : Takeda), Pantoprazole (Protonix Registered : Pfizer), Rabeprazole (Aciphex Registered : Waylis), Vonoprazan (Voquezna Registered : Phathom).
Media Contact
Company Name: ISOThrive Inc
Contact Person: Jack Oswald
Email: Send Email [http://www.universalpressrelease.com/?pr=isothrive-announces-promising-phase-2-interim-data-for-novel-heartburn-treatment-and-appoints-pharma-veteran-mike-walther-as-chief-strategy-officer]
Phone: 415-272-6200
Address:2165 Toyon Drive
City: Healdsburg
State: CA
Country: United States
Website: http://ISOThrive.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer here
News-ID: 4088712 • Views: …
More Releases from Getnews
New Book Explores the Ancient Hebrew Name of God and the Scriptural Evidence for …
Image: https://www.aionewswire.com/storage/images/ckeditor//9798892287463-Perfect_1765382027.jpg
A new thought-provoking work, The Mystery of God's Ancient Hebrew Name and Reincarnation Proven in the Scriptures [https://www.amazon.com/dp/B0G1ZDX9YR], dives deeply into two of the most debated and often misunderstood subjects in faith discussions: the original Hebrew name of the Creator and the presence of reincarnation within biblical texts. Drawing from years of study, cross-referenced Scripture, and linguistic research, author Chet Netherly presents a compelling examination centered on restoring long-overlooked…
A Heartfelt Journey Into the Mind of a Young Dreamer Todd Michael Begin Releases …
Image: https://www.aionewswire.com/storage/images/ckeditor//85905104270_1765380679.jpg
Northern Ontario author and longtime educator Todd Michael Begin invites readers into a touching, imaginative, and deeply human story in his debut children's book, My World is Home [https://www.amazon.com/World-Home-Middle-School-Author/dp/1038343143]. Blending slice of life storytelling with whimsical fantasy, Begin captures a week in the life of a young boy who navigates everyday challenges while escaping into a world of vivid daydreams where ordinary people become creatures, friends, or heroes.
Written with…
Federixa & BEAX release their electronic music
Image: https://www.globalnewslines.com/uploads/2025/12/5f95777dcc1e2dcc357a8a1d12fb3e49.jpg
Experimentation and creativity with over 100 official tracks at just 10 and 8 years old
Federixa (10 years old) and BEAX (8 years old) are two young Italian producers and songwriters with an overwhelming passion for electronic music. They don't sing, but they produce, write, and create original sounds ranging from Tech House to Melodic Techno, from Electro Dance to Electronic Hip Hop. Despite their young age, they are already…
brainSHARE Founder and Chamber Board Member Joe Siecinski Launches Complimentary …
Image: https://www.globalnewslines.com/uploads/2025/12/1765328151.jpg
"I can't stop the business ground from shifting. But through this program, I can help owners strengthen the systems and human connection they need to find their footing and move forward with confidence. That's why this matters now more than ever." - Joe Siecinski, Founder: brainShare Business Mentors.
brainSHARE Founder Joe Siecinski is offering new Silicon Valley Chamber members two months of free access to The Success Circle, helping business…
More Releases for ISOThrive
Animal Microbiome Market Latest Trends and Growth Factors Analysis 2024 to 2031
Animal Microbiome Market worth $12.4 Billion by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd.'s recently published report, "Global Animal Microbiome Market- By Trends, Industry Competition Analysis, Revenue (US$ Millions) and Forecast Till 2030," provides an in-depth analysis and comprehensive study of the market, examining its key factors.
Get Free Access to Demo Report, Excel Pivot and ToC: www.insightaceanalytic.com/request-sample/1046
According to the most recent market intelligence research report by InsightAce…
Functional Dyspepsia Market Size is Set for Rapid Growth as Innovative Treatment …
The Functional Dyspepsia market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Daewoong Pharmaceutical Co Ltd, ISOThrive Inc, Mitsubishi Tanabe Pharma Corp, RaQualia Pharma Inc,Renexxion LLC, Zeria Pharmaceutical Co Ltd., GlaxoSmithKline, Abbott, Dexa Medica Group, Astellas Pharma Inc, Eisai Co., Ltd., Forest Laboratories, Novartis, Bayer
[Nevada, United States] - DelveInsight's "Functional Dyspepsia Market Insights,…
Functional Dyspepsia Market Forecasts by DelveInsight Signal Groundbreaking Grow …
DelveInsight's "Functional Dyspepsia Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Functional Dyspepsia Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The market report covers emerging drugs, treatment practices, market share of individual Functional Dyspepsia therapies, and current & forecasted…
Animal Microbiome Market Survey Detailed Analysis and Forecast 2023-2031
The newly published report titled "Global Animal Microbiome Market- By Trends, Industry Competition Analysis, Revenue (US$ Millions) and Forecast Till 2030." of InsightAce Analytic Pvt. Ltd. features in-depth analysis and an extensive study on the market, exploring its significant factors.
The Animal Microbiome Market Size is valued at 6241.41 Million in 2022 and is predicted to reach 13687.71 Million by the year 2031 at a 9.2 % CAGR during the forecast…
Dyspepsia Market to Grow Rapidly During the Forecast Period (2019-2032) -DelveIn …
DelveInsight's Dyspepsia Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Dyspepsia Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Dyspepsia Market report covers emerging drugs, current treatment practices, market share of individual therapies, and the current forecasted market size from 2019 to…
Human Microbiome Modulators Market Analysis By Type, Application, Growth, Demand …
Worldwide Human Microbiome Modulators Market 2022 Research Report presents a professional and complete analysis of the Global Human Microbiome Modulators Market on the current situation. This report includes development plans and policies along with Human Microbiome Modulators manufacturing processes and price structures. the reports 2022 research report offers an analytical view of the industry by studying different factors like Human Microbiome Modulators Market growth, consumption volume, Market Size, Revenue,…
